At the University of Texas MD Anderson Cancer Center, researchers have engineered a new way to deliver an entire disease-fighting gene into the muscles of people with Duchenne muscular dystrophy—using tiny, natural delivery particles that behave more like biological mail carriers than the blunt instruments of earlier treatments. The breakthrough, published in Nature Biomedical Engineering and led by Dr. Betty Kim and Dr. Wen Jiang, harnesses mRNA-loaded extracellular vesicles to restore the body's production of dystrophin, the crucial muscle protein that prevents degeneration in healthy people. In preclinical models, the therapy dramatically improved muscle strength, endurance and function—without the serious side effects that have plagued previous approaches.
Duchenne muscular dystrophy is a devastating genetic disease that strikes primarily young boys, causing progressive muscle weakness as mutations in the DMD gene prevent the body from making dystrophin. The disease unfolds cruelly: children typically show symptoms like delayed walking in early childhood, then gradually lose the ability to move independently, develop spinal curvature and heart problems, and eventually face respiratory failure. The DMD gene is the longest known in the human genome, a fact that has haunted researchers for decades. Existing viral-based gene therapies cannot carry the entire gene, so they deliver shortened versions that provide incomplete protection. These truncated treatments come with a terrible cost: serious toxicities, immune reactions, and in rare cases, death. The consequences have been severe enough that at least one FDA-approved gene therapy was withdrawn from the market.
The new platform overcomes these constraints by using engineered extracellular vesicles—natural nanoscale particles that the body already uses for cell-to-cell communication—as delivery vehicles instead of modified viruses. The researchers engineered these EVs with special molecular tags that direct them specifically to skeletal muscles after injection into the bloodstream. Once there, they unload their cargo: full-length DMD messenger RNA, the complete genetic instructions needed for producing functional dystrophin. When the researchers injected these mRNA-loaded EVs into preclinical models of Duchenne muscular dystrophy, something remarkable happened. The muscles began producing dystrophin protein again. Muscle strength improved. Function was restored. Critically, the treatment remained localized to skeletal muscle tissue, triggered no immune responses, caused no toxicities—even when given repeatedly.
The approach builds on work that mRNA technology developers were honored for at the 2023 Nobel Prize in physiology or medicine. Dr. Kim's team had already demonstrated that mRNA-loaded EVs could enhance cancer immunotherapy responses in glioblastoma patients, proving the platform's versatility. Now they have shown it can deliver an entire disease-causing gene in its full, functional form—something the field has been chasing for years.
The implications ripple forward cautiously. The researchers themselves note that more work is needed before clinical trials begin, including determining whether the therapy can reach cardiac muscles, since heart problems are common in advanced Duchenne disease. But the blueprint is now drawn. After decades of fighting the constraints of a gene too large to safely deliver, researchers have found a biological solution that nature may have been offering all along.